FACTBOX-AstraZeneca's potential coronavirus vaccine

by Reuters
Tuesday, 30 June 2020 09:28 GMT

* For FACTBOX on vaccines and treatments, click: (Adds detail on Brazil, Mexico, WHO statements) June 30 (Reuters) - Mexico is in talks with AstraZeneca, the University of Oxford and China to run trials of experimental COVID-19 vaccines, a senior official said on Monday. Drugmakers are racing to combat the pandemic that has now killed more than 500,000 people. There are no approved treatments or vaccines for COVID-19, but the World Health Organization (WHO) last week said AstraZeneca's shot is the leading candidate. Here are the main details about AstraZeneca's experimental vaccine and steps to agree supply and production deals: TYPE: * The shot, AZD1222, is a recombinant viral vector vaccine developed by Oxford University. * It is licensed to AstraZeneca. * Uses weakened version of a common-cold virus that encodes instructions for making proteins from the novel coronavirus to build immunity. PROTECTION DURATION: * Likely to provide protection for about a year. EXPECTED COST: * An AZD1222 shot would cost about 2.5 euros ($2.8) per dose in Europe, according to Italy's health ministry. * AstraZeneca does not expect to profit from it during the pandemic. * Costs in other regions not disclosed. TRIALS: * Late-stage clinical trials in humans in Britain. * Brazil and South Africa have also begun trials. * United States' backing includes funding for a trial.(https://bit.ly/3hA8T03) * A pig trial showed promise with two shots. TIMELINE: * First indication on efficacy would likely come in June or July. * Data from studies is expected by August to September. * Delivery of first dose expected between September and October. * Experts predict a safe and effective vaccine could take 12-18 months to develop. TARGET DOSES: * More than 2.1 billion TIE-UPS: * Even before indications or conclusive evidence of the vaccine's success or failure, AstraZeneca has signed deals to produce and supply the shot. MANUFACTURING DEALS: (Most recent first) FIRM BASED IN DEAL VALUE FOR FURTHER Fundação Brazil $127 About 30 Osvaldo Cruz million million doses (Fiocruz) Symbiosis Scotland Undisclosed Clinical Pharmaceutical trial supply Cobra U.S. Undisclosed One million Biosciences doses per month Catalent U.S. Undisclosed Vial filling and packaging Emergent U.S. $87 million 300 million BioSolutions doses Serum Institute India Undisclosed One billion of India doses for low and middle-income countries, with 400 million before end of 2020 Oxford UK Undisclosed Undisclosed Biomedica doses SUPPLY DEALS: (Most recent first) REGION/FIRM DOSES FUNDING DELIVERIES FURTHER Daiichi Sankyo Unspecified Unknown Unknown [nL4N2E319 doses to be J] formulated from undiluted solution to be received France, 300 750 By end of [nL8N2DQ0G Germany, Italy million, million 2020 G] and the with option euros Netherlands of under additional Inclusive 100 million Vaccines Alliance (IVA) Italy (part of 75 million 185 By end of [nL8N2DS2X IVA) million 2020 O] euros Serum One Unknown 400 million [nL4N2DH3L Institute of billion, before the Y] India unspecified end of 2020 number of doses will go to India Epidemic 300 million $750 Some before [nFWN2DH0D response group million, end of 2020 K] CEPI and with $383 Vaccine from CEPI alliance GAVI United States 300 million $1.2 By Oct [nL4N2D31M billion 3] United Kingdom 100 million 84 30 million [nL8N2D05G million by K] pounds September ($103 million) * AstraZeneca is also in talks with Japan, Spain, Russia and China. Sources: Reuters reporting, press releases ($1 = 0.8850 euros) ($1 = 0.8156 pounds) (Reporting by Pushkala Aripaka in Bengaluru; editing by Jason Neely)

Our Standards: The Thomson Reuters Trust Principles.